Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab

Documenti analoghi

• Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years
  di: Kingsbury, Daniel J., et al.
  Pubblicazione: (2014)
• Treating to target of minimal disease activity and normal function in polyarticular juvenile idiopathic arthritis with adalimumab: analysis from a phase 3 clinical trial
  di: Ruperto, Nicola, et al.
  Pubblicazione: (2014)
• Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven‐Year Interim Results
  di: Brunner, Hermine I., et al.
  Pubblicazione: (2020)
• PReS-FINAL-2161: Safety and effectiveness of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to <4 years or >=4 years weighing <15 kg
  di: Kingsbury, D, et al.
  Pubblicazione: (2013)
• Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate
  di: Lovell, Daniel J, et al.
  Pubblicazione: (2020)